Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. FENAGESIC-500 TABLET 500 MG [SIN05718P]

FENAGESIC-500 TABLET 500 MG [SIN05718P]

Active ingredients: FENAGESIC-500 TABLET 500 MG

Last updated 26 October 2025

Product Info

FENAGESIC-500 TABLET 500 MG

[SIN05718P]

Product information

Active Ingredient and Strength

MEFENAMIC ACID - 500 MG

Dosage Form

TABLET, FILM COATED

Manufacturer and Country

SUNWARD PHARMACEUTICAL PRIVATE LIMITED - SINGAPORE

Registration Number

SIN05718P

Licence Holder

SUNWARD PHARMACEUTICAL PRIVATE LIMITED

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

M01AG01

Indications:
Mefenamic acid is indicated for the treatment of primary dysmenorrhoea and the relief of moderate pain when therapy will not exceed one week.

Dosage:
Oral administration.
The recommended regimen in acute pain for adults and children over 14 years of age is 500mg as an initial dose followed by 250mg every six hours as needed, usually not to exceed one week.
For the treatment of primary dysmenorrhoea, the recommended dosage is 500mg as an initial dose followed by 250mg every 6 hours, starting with the onset of bleeding and associated symptoms.
Mefenamic acid should not be used for more than 7 days at a time.
After assessing the risk/benefit ratio in each individual patient, the lowest effective dose for the shortest possible duration should be used.

Contraindications:
Mefenamic acid should not be used in patients who have previously exhibited hypersensitivity to it. Because the potential exists for cross-sensitivity to aspirin or other NSAIDs, mefenamic acid should not be given to patients in whom these drugs induce symptoms of bronchospasm, allergic rhinitis or urticaria.
Mefenamic acid is contraindicated in patients with active ulceration or chronic inflammation of either the upper or lower gastrointestinal tract.
Mefenamic acid should be avoided in patients with pre existing renal disease. Since mefenamic acid is eliminated primarily by the kidneys, the drug should not be administered to patients with significantly impaired renal function.
NSAIDS, including mefenamic acid, are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.